Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
Medtronic
Fish and Richardson
McKesson
Queensland Health
Cerilliant
McKinsey
Cipla
Harvard Business School

Generated: June 19, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR TRAMETINIB DIMETHYL SULFOXIDE

« Back to Dashboard

Clinical Trials for trametinib dimethyl sulfoxide

Trial ID Title Status Sponsor Phase Summary
NCT00003697 Dimethylxanthenone Acetic Acid in Treating Patients With Solid Tumors Completed University of Glasgow Phase 1 RATIONALE: Dimethylxanthenone acetic acid may stop the growth of cancer cells by stopping blood flow to the tumor. PURPOSE: Phase I trial to study the effectiveness of dimethylxanthenone acetic acid in treating patients with solid tumors that have not responded to previous therapy.
NCT00016354 Benzoylphenylurea in Treating Patients With Advanced Solid Tumors Completed National Cancer Institute (NCI) Phase 1 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of benzoylphenylurea in treating patients who have advanced solid tumors.
NCT00016354 Benzoylphenylurea in Treating Patients With Advanced Solid Tumors Completed Sidney Kimmel Comprehensive Cancer Center Phase 1 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of benzoylphenylurea in treating patients who have advanced solid tumors.
NCT00118313 Vaccine Therapy With or Without Imiquimod in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma Completed National Cancer Institute (NCI) Phase 1 RATIONALE: Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. Biological therapies, such as imiquimod, may stimulate the immune system in different ways and stop tumor cells from growing. Giving vaccine therapy together with imiquimod after surgery may help the body kill any remaining tumor cells. PURPOSE: This randomized phase I trial is studying the side effects and best way to give vaccine therapy with or without imiquimod in treating patients who have undergone surgery for stage II, stage III, or stage IV melanoma.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Clinical Trial Conditions for trametinib dimethyl sulfoxide

Condition Name

Condition Name for trametinib dimethyl sulfoxide
Intervention Trials
Melanoma 27
Multiple Sclerosis 17
Cancer 13
Relapsing-Remitting Multiple Sclerosis 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for trametinib dimethyl sulfoxide
Intervention Trials
Melanoma 56
Multiple Sclerosis 38
Sclerosis 34
Multiple Sclerosis, Relapsing-Remitting 21
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for trametinib dimethyl sulfoxide

Trials by Country

Trials by Country for trametinib dimethyl sulfoxide
Location Trials
United States 727
Germany 73
Canada 53
France 52
United Kingdom 45
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for trametinib dimethyl sulfoxide
Location Trials
Texas 43
California 40
Massachusetts 39
New York 33
Florida 32
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for trametinib dimethyl sulfoxide

Clinical Trial Phase

Clinical Trial Phase for trametinib dimethyl sulfoxide
Clinical Trial Phase Trials
Phase 4 24
Phase 3 21
Phase 2/Phase 3 4
[disabled in preview] 60
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for trametinib dimethyl sulfoxide
Clinical Trial Phase Trials
Recruiting 66
Completed 45
Not yet recruiting 29
[disabled in preview] 26
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for trametinib dimethyl sulfoxide

Sponsor Name

Sponsor Name for trametinib dimethyl sulfoxide
Sponsor Trials
Biogen 35
National Cancer Institute (NCI) 33
GlaxoSmithKline 32
[disabled in preview] 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for trametinib dimethyl sulfoxide
Sponsor Trials
Industry 136
Other 126
NIH 36
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Medtronic
Teva
AstraZeneca
McKinsey
Boehringer Ingelheim
QuintilesIMS
Healthtrust
Covington
Chubb

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.